Influence of Montelukast Combined With Methylprednisolone on Liver Function, Platelet Count, Eosinophil Count, and Myocardial Enzymes in Bronchopneumonia Children With Wheezing

<b>Aims/Background</b> Bronchopneumonia is a common infectious disease in pediatrics, which can lead to myocardial and hepatic impairments. Children with bronchopneumonia accompanied by wheezing are vulnerable to hypoxia, which may damage other systems. Therefore, this study explored the influence of montelukast combined with methylprednisolone on liver function, platelet count, eosinophil count, and myocardial enzymes in children with bronchopneumonia accompanied by wheezing. <b>Methods</b> The clinical data of this retrospective study included 82 pediatric cases diagnosed with bronchopneumonia and wheezing between April 2022 and April 2024. Based on treatment methods, patients were divided into the methylprednisolone group (40 cases) as well as the montelukast and methylprednisolone group (42 cases). Therapeutic efficacy, resolution time of clinical symptoms, and adverse effects were recorded. Furthermore, liver function indicators, platelet count, eosinophil count, and myocardial enzyme levels were comparatively assessed using biochemical analyzer, hematology analyzer and biological kits in both groups. <b>Results</b> The total efficacy rate of the montelukast and methylprednisolone group was 95.2% (40/42), higher than the 77.5% of the methylprednisolone group (<i>p</i> = 0.018). Patients in the montelukast and methylprednisolone group had shorter hospitalization and clinical symptom disappearance times than the methylprednisolone group (both <i>p</i> < 0.05). In addition, there was no significant difference in total incidence of adverse reactions (<i>p</i> = 0.700). Methylprednisolone monotherapy or in combination with montelukast, substantially reduced liver function indicators, platelet count, eosinophil count, and myocardial enzyme levels (<i>p</i> < 0.05). Moreover, the platelet count, eosinophil count, and myocardial enzymes [aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK), and creatine kinase isoenzyme (CK-MB)] were reduced in the montelukast and methylprednisolone group compared to the methylprednisolone group after treatment (<i>p</i> < 0.05). Compared to the methylprednisolone group, alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL), direct bilirubin (DBIL) levels were significantly diminished in the montelukast and methylprednisolone group following treatment (<i>p</i> < 0.05). <b>Conclusion</b> Montelukast and methylprednisolone combination therapy reduces platelet and eosinophil counts, alleviates myocardial and liver function damage, and demonstrates good therapeutic efficacy in children with bronchopneumonia accompanied by wheezing.